See more : Hung Fook Tong Group Holdings Limited (1446.HK) Income Statement Analysis – Financial Results
Complete financial analysis of BioVaxys Technology Corp. (BVAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVaxys Technology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Addnode Group AB (publ) (0GMG.L) Income Statement Analysis – Financial Results
- Comms Group Limited (CCG.AX) Income Statement Analysis – Financial Results
- Bryah Resources Limited (BYH.AX) Income Statement Analysis – Financial Results
- AnalytixInsight Inc. (ATIXF) Income Statement Analysis – Financial Results
- Huntington Bancshares Incorporated (HBANL) Income Statement Analysis – Financial Results
BioVaxys Technology Corp. (BVAXF)
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 133.73K | 962.71K | 726.06K | 238.77K | 0.00 |
General & Administrative | 2.11M | 2.94M | 4.00M | 775.10K | 229.91K |
Selling & Marketing | 156.88K | 174.30K | 1.72M | 84.51K | 0.00 |
SG&A | 2.27M | 3.12M | 5.72M | 859.61K | 229.91K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
Cost & Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
Interest Income | 24.85K | 15.77K | 7.66K | 137.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.40M | 3.80M | 5.98M | 1.01M | 183.34K |
EBITDA | 0.00 | 3.58M | 0.00 | 0.00 | 0.00 |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -2.40M | 3.58M | -6.42M | -1.09M | -229.70K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -5.28M | -7.92M | -478.68K | -93.55K | -33.54K |
Income Before Tax | -7.69M | -11.73M | -6.46M | -1.10M | -230.12K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 7.64M | 9.93K | 71.69K | 29.66 |
Net Income | -7.69M | -11.73M | -6.46M | -1.17M | -230.12K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
EPS Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
Weighted Avg Shares Out | 134.15M | 98.18M | 82.93M | 30.05M | 11.02M |
Weighted Avg Shares Out (Dil) | 134.14M | 98.18M | 82.93M | 28.21M | 10.39M |
Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE
Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
Source: https://incomestatements.info
Category: Stock Reports